MXPA05009885A - Nuevas triazolonas fusionadas y los usos de las mismas. - Google Patents

Nuevas triazolonas fusionadas y los usos de las mismas.

Info

Publication number
MXPA05009885A
MXPA05009885A MXPA05009885A MXPA05009885A MXPA05009885A MX PA05009885 A MXPA05009885 A MX PA05009885A MX PA05009885 A MXPA05009885 A MX PA05009885A MX PA05009885 A MXPA05009885 A MX PA05009885A MX PA05009885 A MXPA05009885 A MX PA05009885A
Authority
MX
Mexico
Prior art keywords
triazolones
novel fused
novel compounds
novel
fused
Prior art date
Application number
MXPA05009885A
Other languages
English (en)
Inventor
Yu Yan
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of MXPA05009885A publication Critical patent/MXPA05009885A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems

Abstract

Esta invencion se refiere a nuevos compuestos que tienen el diagrama estructural (I) y a sus composiciones farmaceuticas y a sus metodos de uso. Estos nuevos compuestos proporcionan un tratamiento o profilaxis de cancer.
MXPA05009885A 2003-03-14 2004-03-10 Nuevas triazolonas fusionadas y los usos de las mismas. MXPA05009885A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US45507303P 2003-03-14 2003-03-14
US46769003P 2003-05-02 2003-05-02
US53634304P 2004-01-14 2004-01-14
PCT/SE2004/000351 WO2004081008A1 (en) 2003-03-14 2004-03-10 Novel fused triazolones and the uses thereof

Publications (1)

Publication Number Publication Date
MXPA05009885A true MXPA05009885A (es) 2005-12-05

Family

ID=32995996

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05009885A MXPA05009885A (es) 2003-03-14 2004-03-10 Nuevas triazolonas fusionadas y los usos de las mismas.

Country Status (10)

Country Link
US (1) US20070149560A1 (es)
EP (1) EP1613625A1 (es)
JP (1) JP2006520397A (es)
KR (1) KR20050119647A (es)
AU (1) AU2004220176A1 (es)
BR (1) BRPI0408256A (es)
CA (1) CA2519107A1 (es)
MX (1) MXPA05009885A (es)
NO (1) NO20054083L (es)
WO (1) WO2004081008A1 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7576085B2 (en) * 2002-09-23 2009-08-18 Schering Corporation Imidazopyrazines as cyclin dependent kinase inhibitors
EP1704856A4 (en) * 2003-12-26 2009-08-19 Kyowa Hakko Kirin Co Ltd PROTEIN INHIBITOR OF THE HSP90 FAMILY
JP5038912B2 (ja) 2005-02-16 2012-10-03 アナコール ファーマシューティカルズ，インコーポレイテッド ホウ素含有小分子
PT1853721E (pt) * 2005-02-18 2010-06-08 Astrazeneca Ab Método para determinar a sensibilidade a inibidores de chk1
CA2628455A1 (en) * 2005-11-10 2007-05-24 Schering Corporation Imidazopyrazines as protein kinase inhibitors
CN102532180B (zh) * 2005-12-30 2016-06-29 安纳考尔医药公司 含硼的小分子
CN106008583A (zh) 2005-12-30 2016-10-12 安纳考尔医药公司 含硼的小分子
EP1978966A4 (en) * 2006-01-23 2010-11-10 Amira Pharmaceuticals Inc TRICYCLIC INHIBITORS OF 5-LIPOXYGENASE
TW200806670A (en) * 2006-04-25 2008-02-01 Merck & Co Inc Inhibitors of checkpoint kinases
JO3598B1 (ar) * 2006-10-10 2020-07-05 Infinity Discovery Inc الاحماض والاسترات البورونية كمثبطات اميد هيدروليز الحامض الدهني
WO2008133753A2 (en) * 2006-12-20 2008-11-06 Abbott Laboratories Anti-viral compounds
ES2404668T3 (es) 2006-12-29 2013-05-28 Rigel Pharmaceuticals, Inc. Triazoles sustituidos con arilo bicíclico puenteado y heteroarilo bicíclico puenteado, útiles como agentes inhibidores del axl
WO2009002955A1 (en) * 2007-06-27 2008-12-31 Sanofi-Aventis U.S. Llc Process for the preparation of (2r)-2-[4-(7-bromo-2-quinolyloxy)phenoxy]propanoic acid
CN102046179B (zh) 2008-04-09 2015-01-14 英菲尼提制药公司 脂肪酸酰胺水解酶抑制剂
AR071717A1 (es) 2008-05-13 2010-07-07 Array Biopharma Inc Pirrolo[2,3-b]piridinas inhibidoras de quinasas chk1 y chk2,composiciones farmaceuticas que las contienen,proceso para prepararlas y uso de las mismas en el tratamiento y prevencion del cancer.
WO2010004319A1 (en) * 2008-07-07 2010-01-14 Astrazeneca Ab Combination comprising 6-flu0r0-n- ((1s, 4s) - 4- (6-fluoro-2, 4-di0x0-1- (4'- (piperazin-1- ylmethyl) biphenyl- 3-yl) -1, 2-dihydropyrido [2, 3-d] pyrimidin-3 (4h) - yl) cyclohexyl) imidazo [1,2-a] pyridine -2- carboxamide or a salt
AU2010204578B2 (en) 2009-01-16 2016-05-12 Rigel Pharmaceuticals, Inc. AXL inhibitors for use in combination therapy for preventing, treating or managing metastatic cancer
WO2010104933A1 (en) 2009-03-11 2010-09-16 Merck Sharp & Dohme Corp. Inhibitors of akt activity
JP2012523425A (ja) 2009-04-07 2012-10-04 インフイニトイ プハルマセウトイカルス インコーポレイテッド 脂肪酸アミドヒドロラーゼの阻害薬
AU2010234445A1 (en) 2009-04-07 2011-11-03 Infinity Pharmaceuticals, Inc. Inhibitors of fatty acid amide hydrolase
KR101888026B1 (ko) 2010-02-03 2018-08-13 인피니티 파마슈티컬스, 인코포레이티드 지방산 아미드 하이드롤라제 저해제
WO2014060381A1 (de) 2012-10-18 2014-04-24 Bayer Cropscience Ag Heterocyclische verbindungen als schädlingsbekämpfungsmittel
WO2014067962A1 (de) 2012-10-31 2014-05-08 Bayer Cropscience Ag Neue heterocylische verbindungen als schädlingsbekämpfungsmittel
KR102164612B1 (ko) * 2014-04-24 2020-10-12 동아에스티 주식회사 아졸계 화합물 및 이를 포함하는 선택적 안드로겐 수용체 효능제
EP3461480A1 (en) 2017-09-27 2019-04-03 Onxeo Combination of a dna damage response cell cycle checkpoint inhibitors and belinostat for treating cancer
WO2023165528A1 (en) * 2022-03-01 2023-09-07 Insilico Medicine Ip Limited Diacylglycerol kinase (dgk) alpha inhibitors and uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3953457A (en) * 1972-07-28 1976-04-27 Eli Lilly And Company Agent for the control of plant-pathogenic organisms
US4252806A (en) * 1979-09-24 1981-02-24 Mead Johnson & Company Triazoloquinolones

Also Published As

Publication number Publication date
AU2004220176A1 (en) 2004-09-23
EP1613625A1 (en) 2006-01-11
NO20054083D0 (no) 2005-09-02
CA2519107A1 (en) 2004-09-23
WO2004081008A1 (en) 2004-09-23
NO20054083L (no) 2005-10-10
JP2006520397A (ja) 2006-09-07
BRPI0408256A (pt) 2006-03-01
KR20050119647A (ko) 2005-12-21
US20070149560A1 (en) 2007-06-28

Similar Documents

Publication Publication Date Title
MXPA05009885A (es) Nuevas triazolonas fusionadas y los usos de las mismas.
MY141233A (en) Enantiomers of selected fused heterocyclics and uses thereof
TW200508214A (en) Novel compounds
TW200716606A (en) Chemical compounds
TW200800963A (en) Chemical compounds
HK1113352A1 (en) Chemical compounds
HK1114375A1 (en) Chemical compounds
NO20055130L (no) Aminocykloheksyleter-forbindelser og deres anvendelse
BG66084B1 (bg) Циклопентаноиндоли, състави,съдържащи такива съединения и използването им
TW200714604A (en) Substituted heterocycles and the uses thereof
RS20050070A (en) Use of 1kb kinase inhibitors for the treatment of pain
UA90698C2 (en) Triazole substituted aminobenzophenone compounds
TW200740812A (en) 1,4-Dihydropyridine-fused heterocycles, process for preparing the same, use and compositions containing them
MXPA05013549A (es) Derivados de tienopirimidina como inhibidores del canal de potasio.
SE0203825D0 (sv) Novel fused heterocycles and uses thereof
MX2007001954A (es) Heterociclicos fusionados seleccionados y sus usos.
YU102503A (sh) Kondenzovani pirimidinski dhfr inhibitori kao antibakterijska sredstva
MXPA04002042A (es) Compuestos de bencimidazol sustituidos y su uso para el tratamiento del cancer.
WO2005046587A3 (en) Preparation and composition of inter-alpha inhibitor proteins from human plasma for therapeutic use
MXPA04003755A (es) Endoprotesis vasculares.
TW200510427A (en) Novel fused heterocycles and uses thereof
EP1551388A4 (en) COMPOUNDS USEFUL IN THE TREATMENT OF CANCER, COMPOSITIONS AND METHODS COMPRISING THE SAME
DE60316128D1 (de) N-sulfonylurea-apoptosis-förderer
MXPA03005374A (es) Carbazoles antitumorales.
TNSN07300A1 (en) 1,3-thiazole-5-carboxamides useful as cancer chemotherapeutic agents

Legal Events

Date Code Title Description
FA Abandonment or withdrawal